Reading path

How to Read an Oncology Trial

Cancer studies speak their own language: response rates, progression-free survival, hazard ratios, and biomarkers that decide who a drug is even meant for. This path walks you through that vocabulary in the order it matters, so you can open an oncology trial and tell a real survival benefit from a shrinking tumor that may not change how long someone lives. By the end you will read cancer evidence the way an appraiser does, asking what was measured and whether it counts.

The path, step by step

  1. 1 How Cancer Staging Works and Why Stage Predicts Outcome

    5 min read

    Start with the shared vocabulary of tumor size, nodes, and stage groups, because every oncology trial describes its patients in these terms before it reports a single result.

  2. 2 How Tumor Response Is Measured and Where RECIST Falls Short

    5 min read

    Next, see exactly how a scan gets turned into response or progression under RECIST, and where those rules break, since almost every tumor endpoint is built on this measurement.

  3. 3 Reading an Objective Response Rate in a Cancer Study

    4 min read

    With response defined, learn what objective response rate and duration of response actually promise, the endpoints that carry early-phase cancer trials and the first place hype creeps in.

  4. 4 Why Overall Survival Is the Gold Standard in Cancer Trials

    5 min read

    Now weigh those tumor measures against overall survival, the outcome that asks the real question of whether patients live longer rather than whether their scans looked better.

  5. 5 Surrogate Endpoints Versus Outcomes in Diabetes Trials

    6 min read

    Step back to the general principle beneath any surrogate marker, including progression-free survival and response, and see why moving a surrogate is not the same as preventing the outcome that matters.

  6. 6 The Accelerated-Approval Bargain: Surrogate Endpoints, Confirmatory Trials, and Faster Withdrawal

    5 min read

    See what happens when regulators accept a surrogate anyway, and why the confirmatory-trial bargain determines whether an early cancer approval ever gets confirmed or withdrawn.

  7. 7 How to Read a Cancer Survival Statistic

    5 min read

    Return to survival with sharper eyes, learning how lead-time and length-time bias can inflate a five-year figure so you do not mistake earlier detection for longer life.

  8. 8 Predictive Versus Prognostic Cancer Biomarkers Explained

    5 min read

    Move into precision oncology by separating biomarkers that forecast prognosis from those that actually predict who benefits from a drug, a distinction that decides how a trial's subgroups should be read.

  9. 9 What ctDNA Minimal Residual Disease Testing Can and Cannot Do

    5 min read

    End at the frontier with circulating tumor DNA, a strong prognostic signal that is not yet proof a treatment works, showing how to hold an emerging endpoint to the same standard as the rest.

Each step is a full article on the Reading the Evidence blog.

Back to all reading paths